At GBS, we're focused on one and only one mission: to help talented entrepreneurs build great life science technology companies.

Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

25 / 11 / 2025

> Read More

Otsuka Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)

27 / 10 / 2023

> Read More

FDA Authorizes Marketing of MISHA™ Knee System for People Suffering from Knee Osteoarthritis

10 / 04 / 2023

> Read More